KLAS Contact
Contact KLAS
Contact KLAS
2024 BEST IN KLAS
Preferences
Related Series
US Digital Pathology 2023
A Deep Dive into Early Clinical Adopters’ Successes and Lessons Learned
Author
Eder Lagemann
Author
Sidney Tate
More healthcare organizations are evaluating digital pathology for clinical use, especially as this market’s technology continues to advance and newly developed CPT codes show promise for future reimbursements. Still, digital pathology in the US is nascent—KLAS estimates that fewer than 10% of US organizations have adopted digital pathology for clinical use, and less than 5% of cases are signed out digitally. As a result, organizations interested in digital pathology have questions about how to start and what to expect. To help provide needed insights, this report draws from interviews with 14 digital pathology pioneers who are in varying stages of their adoption journey, sharing lessons they have learned around (1) building a business case for digital pathology, (2) selecting an IMS vendor, and (3) choosing an adoption strategy. View the full report to read more from the early adopters who shared their success stories and adoption details. This is KLAS’ second report on digital pathology in the US; for the 2022 report, click here.
If you don't have a login, getting started is easy.
Key Findings:
- Building a Business Case for Digital Pathology
- Have Early Adopters Seen Standout Success?
- Will Cost Savings Offset the Investment in Digital Pathology?
- Selecting the Right IMS Vendor Partner
- How Should FDA Clearance Factor into a Purchasing Decision?
- Determining the Optimal Adoption Strategy for Your Organization
Writer
Sarah Hanson
Designer
Breanne Hunter
Project Manager
Sydney Toomer
This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.